May 30 |
Genprex to Present at the 2024 BIO International Convention
|
May 15 |
Genprex dosing subjects in trial of combination therapy for small-cell lung cancer
|
May 14 |
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
|
May 9 |
Genprex co-founder, CEO passes away
|
May 8 |
Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner
|
May 7 |
Sidoti Events, LLC's Virtual May Micro-Cap Conference
|
Apr 4 |
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
|
Apr 3 |
Genprex expands clinical trial sites for study to treat small cell lung cancer
|
Apr 3 |
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
|
Apr 2 |
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
|